Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 11, 2015

View Archived Issues

RetroSense Therapeutics initiates phase I/IIa study of RST-001 gene therapy for retinitis pigmentosa

Shire's hCFTR-mRNA-bPEI obtains FDA orphan designation for the treatment of cystic fibrosis

First-in-human, phase I, dose-escalation study of TAS-116

AstraZeneca initiates phase I study of AZD-8871 for asthma and COPD

Antitumor efficacy of anti-HER2 ADC DS-8201a versus trastuzumab emtansine

Eiger signs license agreement with Nippon Kayaku to develop Bestatin for PAH

Foundation Fighting Blindness provides funding to develop VM-200 for Stargardt disease

Chromosome 19 harbors susceptibility genes for panic disorder

Polymorphisms in SIGMAR1 gene may be associated with bipolar disorder

New plasma metabolomics biomarker panel to predict phenoconversion risk

CymaBay Therapeutics confirms initiation of phase II study of MBX-8025

XBiotech discovers neutralizing antibodies for Ebola virus

Boston Scientific agrees to acquire CeloNova's radiology business

FDA approves cobimetinib in combination with vemurafenib for advanced melanoma

MMV grant supports malaria drug development at QIMR Berghofer

Immuron collaborates with OWL Metabolomics on NASH companion diagnostic to IMM-124-E

Tolero licenses use of Eutropics' PraediCare Dx for alvocidib clinical program

Mayo Clinic describes novel drug candidate for cardiorenal disease

WuXi PharmaTech and Lilly to codevelop drug for patients with dyslipidemia in China

Cidara Therapeutics patents bifunctional antifungal agents

Dong-A ST divulges androgen receptor agonists

Antimalarials targeting apicoplast optimized to derive MMV-008138

Takeda Pharmaceutical discloses muscarinic M1 PAMs

GKT-137831 receives orphan drug designation in the E.U. for systemic sclerosis

Novartis describes PI3Kgamma inhibitors

Vitae Pharmaceuticals presents CD73 inhibitors

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 5, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...
Janssen Pharmaceutica reports new TMEM175 activators
BioWorld Science
Janssen Pharmaceutica NV has identified new endosomal/lysosomal proton channel TMEM175 activators that are potentially useful for the treatment of Parkinson’s...